Researchers Studying Oral Medicine for Solid Tumors Dependent on KIT or PDGFRA Signaling
Phase: Recruiting
First Posted: February
Condition(s): Central Nervous System (CNS) Tumor
NCT Number: NCT04773782 Other Study ID Number(s): ROVER
What Is the Purpose of This Study?
To determine if oral medication Avapritinib is safe and effective in treating pediatric patients with solid tumors that depend on KIT or PDGFRA signaling.
Who Can Take Part in This Study?
People who may be eligible for this study:
- Have confirmed diagnosis of R/R solid tumor, including CNS tumors, with a mutation in PDGFRA and/or KIT that has progressed and no alternative treatment options are available.
- Have confirmed diagnosis of DMG-H3K27a that has failed standard therapy or for which no standard therapy is available.
- Are 2-17 years old.
For a full list of eligibility requirements, visit https://clinicaltrials.gov/study/NCT04773782
What Will Happen During This Study?
Patients will take daily oral medication continuously one time a day for 28-day cycles. There is no limit on number of treatment cycles.
Principal Investigator
Discover More Research
Explore additional studies relating to neuro-oncologyYour Might Also Be Interested In
Neuro-Oncology
Our highly experienced and internationally recognized team of pediatric neuro-oncologists, neurosurgeons and neuroradiologists will care for your child by providing the most advanced and innovative treatments, while at the same time, paying careful attention to all the needs and concerns of your child and family.
Central Nervous System (CNS) Tumor
The central nervous system is made up of the brain and the spinal cord. This system is responsible for sending, receiving and processing information throughout your body, controlling how your body functions. When tumors grow in the central nervous system, they can cause significant symptoms.
Brain Tumors
Brain tumors are the most common solid tumors in children. Primary brain tumors start in the brain and usually do not spread outside the brain tissue.